




SUPPLEMENTARY FIGURES



Supplementary Figure 1. Validation of exosome purification. (A) Size distribution of exosomes in control, hepatitis, cirrhosis, and HCC groups. (B) Western blot analysis of exosome-specific proteins (CD63, TSG101, and CD9) in control, hepatitis, cirrhosis, and HCC groups and calnexin protein analysis in control, hepatitis, cirrhosis, and HCC groups and HepG2 and MHCC-LM3 cells. HCC, hepatocellular carcinoma.



Supplementary Figure 2. Relative lnc-FAM72D-3, lnc-EPC1-4, lnc-ZEB2-19, and lnc-GPR89B-15 expression in different cell lines determined by real-time qPCR. qPCR, quantitative polymerase chain reaction.



Supplementary Figure 3. Suppression and overexpression of lnc-FAM72D-3 and lnc-EPC1-4 in different cells. (A) lnc-FAM72D-3 expression in different cells treated with siRNA and lnc-FAM72D-3 overexpression vector. **(B)** lnc-EPC1-4 expression in different cells treated with siRNA and lnc-EPC1-4 overexpression vector. siRNA, small interfering RNA.